Ubiquitination network in the type I IFN‐induced antiviral signaling pathway

Type I IFN (IFN‐I) is the body's first line of defense against pathogen infection. IFN‐I can induce cellular antiviral responses and therefore plays a key role in driving antiviral innate and adaptive immunity. Canonical IFN‐I signaling activates the Janus kinase (JAK)/signal transducer and activator of transcription (STAT) pathway, which induces the expression of IFN‐stimulated genes and eventually establishes a complex antiviral state in the cells. Ubiquitin is a ubiquitous cellular molecule for protein modifications, and the ubiquitination modifications of protein have been recognized as one of the key modifications that regulate protein levels and/or signaling activation. Despite great advances in understanding the ubiquitination regulation of many signaling pathways, the mechanisms by which protein ubiquitination regulates IFN‐I‐induced antiviral signaling have not been explored until very recently. This review details the current understanding of the regulatory network of ubiquitination that critically controls the IFN‐I‐induced antiviral signaling pathway from three main levels, including IFN‐I receptors, IFN‐I‐induced cascade signals, and effector IFN‐stimulated genes.

[1]  Wen Zhang,et al.  E3 Ubiquitin Ligases: The Operators of the Ubiquitin Code That Regulates the RLR and cGAS-STING Pathways , 2022, International journal of molecular sciences.

[2]  J. Patton,et al.  Rotavirus NSP1 Subverts the Antiviral Oligoadenylate Synthetase-RNase L Pathway by Inducing RNase L Degradation , 2022, mBio.

[3]  S. Lippman,et al.  JAK: Not Just Another Kinase. , 2022, Molecular cancer therapeutics.

[4]  Xiaolong Wang,et al.  CircRNA-CREIT inhibits stress granule assembly and overcomes doxorubicin resistance in TNBC by destabilizing PKR , 2022, Journal of Hematology & Oncology.

[5]  Bin Wang,et al.  Depression compromises antiviral innate immunity via the AVP-AHI1-Tyk2 axis , 2022, Cell Research.

[6]  H. Lv,et al.  E3 ubiquitin ligase MID1 ubiquitinates and degrades type‐I interferon receptor 2 , 2022, Immunology.

[7]  Qian Wang,et al.  Down-regulation of circPTTG1IP induces hepatocellular carcinoma development via miR-16-5p/RNF125/JAK1 axis. , 2022, Cancer letters.

[8]  Chuanwu Zhu,et al.  LATS1 is a central signal transmitter for achieving full type-I interferon activity , 2022, Science advances.

[9]  Z. Liu,et al.  The E3 ubiquitin ligase, FBXW5, promotes the migration and invasion of gastric cancer through the dysregulation of the Hippo pathway , 2022, Cell death discovery.

[10]  Xiaoying Hu,et al.  The JAK/STAT signaling pathway: from bench to clinic , 2021, Signal Transduction and Targeted Therapy.

[11]  Chuanwu Zhu,et al.  High salt activates p97 to reduce host antiviral immunity by restricting Viperin induction , 2021, EMBO reports.

[12]  Jieliang Chen,et al.  Interferon and Hepatitis B: Current and Future Perspectives , 2021, Frontiers in Immunology.

[13]  Jun Wang,et al.  HSV-1-encoded ICP0 degrades the host deubiquitinase BRCC36 to antagonize interferon antiviral response. , 2021, Molecular immunology.

[14]  E. Marsh,et al.  The Antiviral Enzyme, Viperin, Activates Protein Ubiquitination by the E3 Ubiquitin Ligase, TRAF6 , 2021, bioRxiv.

[15]  C. Lamaze,et al.  Interferon Receptor Trafficking and Signaling: Journey to the Cross Roads , 2021, Frontiers in Immunology.

[16]  Shitao Li,et al.  Role of Post-Translational Modifications of cGAS in Innate Immunity , 2020, International journal of molecular sciences.

[17]  Liping Wang,et al.  Roles of IFN-γ in tumor progression and regression: a review , 2020, Biomarker research.

[18]  P. Ma,et al.  RNF220 mediates K63-linked polyubiquitination of STAT1 and promotes host defense , 2020, Cell Death & Differentiation.

[19]  E. Kudryashova,et al.  Opposing activities of IFITM proteins in SARS-CoV-2 infection , 2020, bioRxiv.

[20]  Qinxue Hu,et al.  Herpes Simplex Virus Type 2 Inhibits Type I IFN Signaling Mediated by the Novel E3 Ubiquitin Protein Ligase Activity of Viral Protein ICP22 , 2020, The Journal of Immunology.

[21]  V. Saini,et al.  Impact and prognosis of the expression of IFN-α among tuberculosis patients , 2020, PloS one.

[22]  H. Oshiumi Recent Advances and Contradictions in the Study of the Individual Roles of Ubiquitin Ligases That Regulate RIG-I-Like Receptor-Mediated Antiviral Innate Immune Responses , 2020, Frontiers in Immunology.

[23]  Jun Wang,et al.  Regulation of the linear ubiquitination of STAT1 controls antiviral interferon signaling , 2020, Nature Communications.

[24]  Guang-Hui Qian,et al.  Small‐molecule inhibitors of ubiquitin‐specific protease 7 enhance type‐I interferon antiviral efficacy by destabilizing SOCS1 , 2020 .

[25]  Depei Wu,et al.  BRCC36 functions noncatalytically to promote antiviral response by maintaining STAT1 protein stability , 2020, European journal of immunology.

[26]  Li Zhu,et al.  USP12 translocation maintains interferon antiviral efficacy by inhibiting CBP acetyltransferase activity , 2020, PLoS pathogens.

[27]  Wei Li,et al.  Targeting UBE4A Revives Viperin Protein in Epithelium to Enhance Host Antiviral Defense. , 2019, Molecular cell.

[28]  I. Dikic,et al.  Cellular quality control by the ubiquitin-proteasome system and autophagy , 2019, Science.

[29]  S. Hohaus,et al.  Clinical and Antitumor Immune Responses in Relapsed/Refractory Follicular Lymphoma Patients after Intranodal Injections of IFNα-Dendritic Cells and Rituximab: a Phase I Clinical Trial , 2019, Clinical Cancer Research.

[30]  Ji-Long Chen,et al.  Functional Involvement of Interferon-Inducible Transmembrane Proteins in Antiviral Immunity , 2019, Front. Microbiol..

[31]  Kailin Xu,et al.  ADP-ribosyltransferase PARP11 modulates the interferon antiviral response by mono-ADP-ribosylating the ubiquitin E3 ligase β-TrCP , 2019, Nature Microbiology.

[32]  David M. Smith,et al.  A Practical Review of Proteasome Pharmacology , 2019, Pharmacological Reviews.

[33]  C. Winkler,et al.  IFITM Genes, Variants, and Their Roles in the Control and Pathogenesis of Viral Infections , 2019, Front. Microbiol..

[34]  Lidong Wang,et al.  RNF168 facilitates proliferation and invasion of esophageal carcinoma, possibly via stabilizing STAT1 , 2018, Journal of cellular and molecular medicine.

[35]  J. Babon,et al.  The molecular details of cytokine signaling via the JAK/STAT pathway , 2018, Protein science : a publication of the Protein Society.

[36]  T. Taniguchi,et al.  The Interferon (IFN) Class of Cytokines and the IFN Regulatory Factor (IRF) Transcription Factor Family. , 2018, Cold Spring Harbor perspectives in biology.

[37]  M. Raza,et al.  Interferon-gamma (IFN-γ): Exploring its implications in infectious diseases , 2018, Biomolecular concepts.

[38]  M. Oliveira,et al.  Interferon-Gamma at the Crossroads of Tumor Immune Surveillance or Evasion , 2018, Front. Immunol..

[39]  Xiaofeng Zheng,et al.  Induction of OTUD1 by RNA viruses potently inhibits innate immune responses by promoting degradation of the MAVS/TRAF3/TRAF6 signalosome , 2018, PLoS pathogens.

[40]  J. Arnold,et al.  A naturally occurring antiviral ribonucleotide encoded by the human genome , 2018, Nature.

[41]  S. Yao,et al.  The molecular basis of JAK/STAT inhibition by SOCS1 , 2018, Nature Communications.

[42]  A. Gatignol,et al.  ADAR1 and PKR, interferon stimulated genes with clashing effects on HIV-1 replication. , 2018, Cytokine & growth factor reviews.

[43]  H. Oshiumi,et al.  Regulation of RIG-I Activation by K63-Linked Polyubiquitination , 2018, Front. Immunol..

[44]  W. Hong,et al.  Deubiquitinating Enzyme USP9X Suppresses Tumor Growth via LATS Kinase and Core Components of the Hippo Pathway. , 2017, Cancer research.

[45]  Peng Zhao,et al.  JOSD1 Negatively Regulates Type-I Interferon Antiviral Activity by Deubiquitinating and Stabilizing SOCS1. , 2017, Viral immunology.

[46]  C. Scagnolari,et al.  Role of Interferons in Chronic Hepatitis C Infection. , 2017, Current drug targets.

[47]  C. Johansson,et al.  Type I Interferons as Regulators of Lung Inflammation , 2017, Front. Immunol..

[48]  Y. Crow,et al.  Type I interferon–mediated monogenic autoinflammation: The type I interferonopathies, a conceptual overview , 2016, The Journal of experimental medicine.

[49]  Manoj N. Krishnan,et al.  Global functional profiling of human ubiquitome identifies E3 ubiquitin ligase DCST1 as a novel negative regulator of Type-I interferon signaling , 2016, Scientific Reports.

[50]  Guang-Hui Qian,et al.  Ubiquitin-dependent Turnover of Adenosine Deaminase Acting on RNA 1 (ADAR1) Is Required for Efficient Antiviral Activity of Type I Interferon* , 2016, The Journal of Biological Chemistry.

[51]  Jianfeng Dai,et al.  Deubiquitinase USP2a Sustains Interferons Antiviral Activity by Restricting Ubiquitination of Activated STAT1 in the Nucleus , 2016, PLoS pathogens.

[52]  A. Brass,et al.  The IFITMs Inhibit Zika Virus Replication. , 2016, Cell reports.

[53]  M. Arnold,et al.  Rotavirus NSP1 Associates with Components of the Cullin RING Ligase Family of E3 Ubiquitin Ligases , 2016, Journal of Virology.

[54]  I. Dikic,et al.  Ubiquitin chain diversity at a glance , 2016, Journal of Cell Science.

[55]  Jun Chen,et al.  Cullin 4A (CUL4A), a direct target of miR-9 and miR-137, promotes gastric cancer proliferation and invasion by regulating the Hippo signaling pathway , 2016, Oncotarget.

[56]  G. Conn,et al.  Adenovirus VA RNA: An essential pro-viral non-coding RNA. , 2016, Virus research.

[57]  H. Ezelle,et al.  International Journal of Molecular Sciences the Roles of Rnase-l in Antimicrobial Immunity and the Cytoskeleton-associated Innate Response , 2022 .

[58]  Nicholas M. Chesarino,et al.  E3 Ubiquitin Ligase NEDD4 Promotes Influenza Virus Infection by Decreasing Levels of the Antiviral Protein IFITM3 , 2015, PLoS pathogens.

[59]  M. Mitkiewicz,et al.  [Ubiquitin as a regulator of IFN production in the antiviral response]. , 2015, Postepy higieny i medycyny doswiadczalnej.

[60]  S. Jonjić,et al.  Varicella Viruses Inhibit Interferon-Stimulated JAK-STAT Signaling through Multiple Mechanisms , 2015, PLoS pathogens.

[61]  A. Oxenius,et al.  Regulation of antiviral T cell responses by type I interferons , 2015, Nature Reviews Immunology.

[62]  S. Bosinger,et al.  Type I Interferon: Understanding Its Role in HIV Pathogenesis and Therapy , 2015, Current HIV/AIDS Reports.

[63]  A. Hauschild,et al.  Who benefits most from adjuvant interferon treatment for melanoma? , 2015, American journal of therapeutics.

[64]  B. Kelsall,et al.  The role of type I interferons in intestinal infection, homeostasis, and inflammation , 2014, Immunological reviews.

[65]  A. Brass,et al.  IFITM3 Restricts Influenza A Virus Entry by Blocking the Formation of Fusion Pores following Virus-Endosome Hemifusion , 2014, PLoS pathogens.

[66]  M. Beard,et al.  The role of viperin in the innate antiviral response. , 2014, Journal of molecular biology.

[67]  Nicholas M. Chesarino,et al.  Phosphorylation of the Antiviral Protein Interferon-inducible Transmembrane Protein 3 (IFITM3) Dually Regulates Its Endocytosis and Ubiquitination* , 2014, The Journal of Biological Chemistry.

[68]  L. Ivashkiv,et al.  Regulation of type I interferon responses , 2013, Nature Reviews Immunology.

[69]  Ping Zhang,et al.  Lack of RNase L Attenuates Macrophage Functions , 2013, PloS one.

[70]  R. Greenberg,et al.  A BRISC-SHMT complex deubiquitinates IFNAR1 and regulates interferon responses. , 2013, Cell reports.

[71]  Han Yang,et al.  Ubiquitin-Specific Protease 13 Regulates IFN Signaling by Stabilizing STAT1 , 2013, The Journal of Immunology.

[72]  B. Williams,et al.  Fine tuning type I interferon responses. , 2013, Cytokine & growth factor reviews.

[73]  Xiaolong Yang,et al.  WWP1 E3 Ligase Targets LATS1 for Ubiquitin-Mediated Degradation in Breast Cancer Cells , 2013, PloS one.

[74]  J. N. Clarke,et al.  Viperin Is Induced following Dengue Virus Type-2 (DENV-2) Infection and Has Anti-viral Actions Requiring the C-terminal End of Viperin , 2013, PLoS neglected tropical diseases.

[75]  U. Dittmer,et al.  IFN‐α subtypes: distinct biological activities in anti‐viral therapy , 2013, British journal of pharmacology.

[76]  D. Taatjes,et al.  CDK8 Kinase Phosphorylates Transcription Factor STAT1 to Selectively Regulate the Interferon Response , 2013, Immunity.

[77]  D. Baker,et al.  Protein tyrosine phosphatase 1B is a key regulator of IFNAR1 endocytosis and a target for antiviral therapies , 2012, Proceedings of the National Academy of Sciences.

[78]  Hideo Negishi,et al.  The IRF family of transcription factors , 2012, Oncoimmunology.

[79]  K. Malathi,et al.  RNase L Induces Autophagy via c-Jun N-terminal Kinase and Double-stranded RNA-dependent Protein Kinase Signaling Pathways* , 2012, The Journal of Biological Chemistry.

[80]  J. Kirkwood,et al.  IFN-α in the Treatment of Melanoma , 2012, The Journal of Immunology.

[81]  N. Nasr,et al.  HIV-1 infection of human macrophages directly induces viperin which inhibits viral production. , 2012, Blood.

[82]  Ceshi Chen,et al.  WWP1: a versatile ubiquitin E3 ligase in signaling and diseases , 2012, Cellular and Molecular Life Sciences.

[83]  J. Darnell,et al.  The JAK-STAT pathway at twenty. , 2012, Immunity.

[84]  R. A. Karssemeijer,et al.  S-Palmitoylation and Ubiquitination Differentially Regulate Interferon-induced Transmembrane Protein 3 (IFITM3)-mediated Resistance to Influenza Virus* , 2012, The Journal of Biological Chemistry.

[85]  Jianni Qi,et al.  Smurf1 Protein Negatively Regulates Interferon-γ Signaling through Promoting STAT1 Protein Ubiquitination and Degradation* , 2012, The Journal of Biological Chemistry.

[86]  Thao Nguyen,et al.  The interferons and their receptors—distribution and regulation , 2012, Immunology and cell biology.

[87]  P. Cresswell,et al.  Viperin: a multifunctional, interferon-inducible protein that regulates virus replication. , 2011, Cell host & microbe.

[88]  S. Lemon,et al.  The antiviral protein viperin inhibits hepatitis C virus replication via interaction with nonstructural protein 5A , 2011, Hepatology.

[89]  Gaurav D. Gaiha,et al.  IFITM3 Inhibits Influenza A Virus Infection by Preventing Cytosolic Entry , 2011, PLoS pathogens.

[90]  D. Baker,et al.  Tyrosine Phosphorylation of Protein Kinase D2 Mediates Ligand-inducible Elimination of the Type 1 Interferon Receptor* , 2011, The Journal of Biological Chemistry.

[91]  Anne Gatignol,et al.  Enhancement of Replication of RNA Viruses by ADAR1 via RNA Editing and Inhibition of RNA-Activated Protein Kinase , 2011, Journal of Virology.

[92]  C. Samuel,et al.  Adenosine deaminases acting on RNA (ADARs) are both antiviral and proviral. , 2011, Virology.

[93]  Y. She,et al.  Itch E3 ubiquitin ligase regulates large tumor suppressor 1 stability , 2011, Proceedings of the National Academy of Sciences.

[94]  A. Kijlstra,et al.  IFN-alpha blocks IL-17 production by peripheral blood mononuclear cells in Behcet's disease. , 2011, Rheumatology.

[95]  D. Baker,et al.  Ligand-Stimulated Downregulation of the Alpha Interferon Receptor: Role of Protein Kinase D2 , 2010, Molecular and Cellular Biology.

[96]  Xiaolong Yang,et al.  LATS tumor suppressor: A new governor of cellular homeostasis , 2010, Cell cycle.

[97]  E. Urcelay,et al.  IFN-beta pharmacogenomics in multiple sclerosis. , 2010, Pharmacogenomics.

[98]  C. Samuel,et al.  RNA adenosine deaminase ADAR1 deficiency leads to increased activation of protein kinase PKR and reduced vesicular stomatitis virus growth following interferon treatment. , 2010, Virology.

[99]  L. Moja,et al.  Interferon-alpha for maintenance of follicular lymphoma. , 2010, The Cochrane database of systematic reviews.

[100]  David J. Adams,et al.  The IFITM Proteins Mediate Cellular Resistance to Influenza A H1N1 Virus, West Nile Virus, and Dengue Virus , 2009, Cell.

[101]  D. Baker,et al.  Inducible Priming Phosphorylation Promotes Ligand-independent Degradation of the IFNAR1 Chain of Type I Interferon Receptor* , 2009, The Journal of Biological Chemistry.

[102]  C. Samuel,et al.  Adenosine deaminase ADAR1 increases gene expression at the translational level by decreasing protein kinase PKR-dependent eIF-2alpha phosphorylation. , 2009, Journal of molecular biology.

[103]  Roberto Cattaneo,et al.  RNA-specific Adenosine Deaminase ADAR1 Suppresses Measles Virus-induced Apoptosis and Activation of Protein Kinase PKR* , 2009, The Journal of Biological Chemistry.

[104]  David Komander,et al.  Breaking the chains: structure and function of the deubiquitinases , 2009, Nature Reviews Molecular Cell Biology.

[105]  O. Crasta,et al.  An essential role for the antiviral endoribonuclease, RNase-L, in antibacterial immunity , 2008, Proceedings of the National Academy of Sciences.

[106]  E. Yang,et al.  Recruitment of Stat1 to chromatin is required for interferon-induced serine phosphorylation of Stat1 transactivation domain , 2008, Proceedings of the National Academy of Sciences.

[107]  D. Alberts,et al.  Randomized phase 3 trial of interferon gamma-1b plus standard carboplatin/paclitaxel versus carboplatin/paclitaxel alone for first-line treatment of advanced ovarian and primary peritoneal carcinomas: results from a prospectively designed analysis of progression-free survival. , 2008, Gynecologic oncology.

[108]  Dong-er Zhang,et al.  ISG15 Inhibits Nedd4 Ubiquitin E3 Activity and Enhances the Innate Antiviral Response*♦ , 2008, Journal of Biological Chemistry.

[109]  T. Taniguchi,et al.  The IRF family transcription factors in immunity and oncogenesis. , 2008, Annual review of immunology.

[110]  D. Baker,et al.  Ligand-independent pathway that controls stability of interferon alpha receptor. , 2008, Biochemical and biophysical research communications.

[111]  B. Ramratnam,et al.  Acetylation-Dependent Signal Transduction for Type I Interferon Receptor , 2007, Cell.

[112]  A. Hovanessian On the discovery of interferon-inducible, double-stranded RNA activated enzymes: the 2'-5'oligoadenylate synthetases and the protein kinase PKR. , 2007, Cytokine & growth factor reviews.

[113]  Peter Cresswell,et al.  The interferon-inducible protein viperin inhibits influenza virus release by perturbing lipid rafts. , 2007, Cell host & microbe.

[114]  R. Silverman,et al.  Small self-RNA generated by RNase L amplifies antiviral innate immunity , 2007, Nature.

[115]  Paul J. Hertzog,et al.  Type I Interferon Receptors: Biochemistry and Biological Functions* , 2007, Journal of Biological Chemistry.

[116]  S. Pestka The Interferons: 50 Years after Their Discovery, There Is Much More to Learn* , 2007, Journal of Biological Chemistry.

[117]  P. Pitha,et al.  The IRF family, revisited. , 2007, Biochimie.

[118]  J. F. Burrows,et al.  Respiratory Syncytial Virus NS1 Protein Degrades STAT2 by Using the Elongin-Cullin E3 Ligase , 2007, Journal of Virology.

[119]  Ulrich Pfeffer,et al.  Identification of Genes Selectively Regulated by IFNs in Endothelial Cells1 , 2007, The Journal of Immunology.

[120]  Y. Nie,et al.  Double-Stranded RNA Deaminase ADAR1 Increases Host Susceptibility to Virus Infection , 2006, Journal of Virology.

[121]  C. Brosnan,et al.  TLR3 Ligation Activates an Antiviral Response in Human Fetal Astrocytes: A Role for Viperin/cig51 , 2006, The Journal of Immunology.

[122]  E. Coccia,et al.  Toll-like Receptor-dependent and -independent Viperin Gene Expression and Counter-regulation by PRDI-binding Factor-1/BLIMP1* , 2006, Journal of Biological Chemistry.

[123]  T. Robak Current treatment options in hairy cell leukemia and hairy cell leukemia variant. , 2006, Cancer treatment reviews.

[124]  S. Fuchs,et al.  TYK2 activity promotes ligand-induced IFNAR1 proteolysis. , 2006, The Biochemical journal.

[125]  L. Semendric,et al.  Analysis of ISG expression in chronic hepatitis C identifies viperin as a potential antiviral effector , 2005, Hepatology.

[126]  Takashi Tanaka,et al.  SLIM is a nuclear ubiquitin E3 ligase that negatively regulates STAT signaling. , 2005, Immunity.

[127]  C. D. Krause,et al.  Interferons, interferon‐like cytokines, and their receptors , 2004, Immunological reviews.

[128]  S. Fuchs,et al.  Phosphorylation and Specific Ubiquitin Acceptor Sites Are Required for Ubiquitination and Degradation of the IFNAR1 Subunit of Type I Interferon Receptor* , 2004, Journal of Biological Chemistry.

[129]  Y. Kitade,et al.  Structural basis for recognition of 2′,5′‐linked oligoadenylates by human ribonuclease L , 2004, The EMBO journal.

[130]  G. Hall,et al.  Maintenance treatment with interferon for advanced ovarian cancer: results of the Northern and Yorkshire gynaecology group randomised phase III study , 2004, British Journal of Cancer.

[131]  Xiaolong Yang,et al.  LATS1 tumour suppressor affects cytokinesis by inhibiting LIMK1 , 2004, Nature Cell Biology.

[132]  T. Pawson,et al.  The Nedd4 family of E3 ubiquitin ligases: functional diversity within a common modular architecture , 2004, Oncogene.

[133]  D. Hilton,et al.  Inhibitors of Cytokine Signal Transduction* , 2004, Journal of Biological Chemistry.

[134]  K. Pfeffer,et al.  Phosphorylation of the Stat1 transactivation domain is required for full-fledged IFN-gamma-dependent innate immunity. , 2003, Immunity.

[135]  T. Decker,et al.  Phosphorylation of the Stat1 transactivating domain is required for the response to type I interferons , 2003, EMBO reports.

[136]  J. Turkson,et al.  STAT3 Activation by Type I Interferons Is Dependent on Specific Tyrosines Located in the Cytoplasmic Domain of Interferon Receptor Chain 2c , 2002, The Journal of Biological Chemistry.

[137]  G. Stark,et al.  Interferon Signaling Is Dependent on Specific Tyrosines Located within the Intracellular Domain of IFNAR2c , 2002, The Journal of Biological Chemistry.

[138]  T. Xu,et al.  Human homologue of Drosophila lats, LATS1, negatively regulate growth by inducing G2/M arrest or apoptosis , 2001, Oncogene.

[139]  I. Kola,et al.  The soluble murine type I interferon receptor Ifnar-2 is present in serum, is independently regulated, and has both agonistic and antagonistic properties. , 2001, Blood.

[140]  C. Horvath,et al.  Interferon regulatory factor subcellular localization is determined by a bipartite nuclear localization signal in the DNA-binding domain and interaction with cytoplasmic retention factors. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[141]  P. Cohen,et al.  Stress-induced phosphorylation of STAT1 at Ser727 requires p38 mitogen-activated protein kinase whereas IFN-gamma uses a different signaling pathway. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[142]  M. S. St John,et al.  The role of lats in cell cycle regulation and tumorigenesis. , 1999, Biochimica et biophysica acta.

[143]  J. Hiscott,et al.  The growing family of interferon regulatory factors. , 1997, Cytokine & growth factor reviews.

[144]  J. Darnell STATs and gene regulation. , 1997, Science.

[145]  M J Clemens,et al.  The double-stranded RNA-dependent protein kinase PKR: structure and function. , 1997, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

[146]  Warren S. Alexander,et al.  A family of cytokine-inducible inhibitors of signalling , 1997, Nature.

[147]  S. Akira,et al.  Structure and function of a new STAT-induced STAT inhibitor , 1997, Nature.

[148]  Takaho A. Endo,et al.  A new protein containing an SH2 domain that inhibits JAK kinases , 1997, Nature.

[149]  G. Stark,et al.  Functional subdomains of STAT2 required for preassociation with the alpha interferon receptor and for signaling , 1997, Molecular and cellular biology.

[150]  J. Mattick,et al.  Cloning and expression analysis of a novel mouse gene with sequence similarity to the Drosophila fat facets gene , 1997, Mechanisms of Development.

[151]  Richard G Richards Interferon beta in multiple sclerosis , 1996, BMJ.

[152]  G. Stark,et al.  Mutant U5A cells are complemented by an interferon‐alpha beta receptor subunit generated by alternative processing of a new member of a cytokine receptor gene cluster. , 1995, The EMBO journal.

[153]  B. Cohen,et al.  Ligand-induced association of the type I interferon receptor components , 1995, Molecular and cellular biology.

[154]  J. Darnell,et al.  Maximal activation of transcription by statl and stat3 requires both tyrosine and serine phosphorylation , 1995, Cell.

[155]  C. Proud,et al.  PKR: a new name and new roles. , 1995, Trends in biochemical sciences.

[156]  T. Xu,et al.  Identifying tumor suppressors in genetic mosaics: the Drosophila lats gene encodes a putative protein kinase. , 1995, Development.

[157]  P J Bryant,et al.  The Drosophila tumor suppressor gene warts encodes a homolog of human myotonic dystrophy kinase and is required for the control of cell shape and proliferation. , 1995, Genes & development.

[158]  O. Colamonici,et al.  Direct binding to and tyrosine phosphorylation of the alpha subunit of the type I interferon receptor by p135tyk2 tyrosine kinase , 1994, Molecular and cellular biology.

[159]  J. Johnston,et al.  Molecular cloning of L-JAK, a Janus family protein-tyrosine kinase expressed in natural killer cells and activated leukocytes. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[160]  E. Génot Interferon alpha and intracytoplasmic free calcium in hairy cell leukemia cells. , 1994, Leukemia & lymphoma.

[161]  P. Lengyel Tumor-suppressor genes: news about the interferon connection. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[162]  C. Samuel,et al.  The eIF-2 alpha protein kinases, regulators of translation in eukaryotes from yeasts to humans. , 1993, The Journal of biological chemistry.

[163]  G. Gahrton,et al.  Natural interferon-alpha in combination with melphalan/prednisone versus melphalan/prednisone in the treatment of multiple myeloma stages II and III: a randomized study from the Myeloma Group of Central Sweden , 1993 .

[164]  S. Vedantham,et al.  Mechanism of interferon action in hairy cell leukemia: a model of effective cancer biotherapy. , 1992, Cancer research.

[165]  C. Samuel,et al.  Antiviral actions of interferon. Interferon-regulated cellular proteins and their surprisingly selective antiviral activities. , 1991, Virology.

[166]  T. Shows,et al.  tyk2, prototype of a novel class of non-receptor tyrosine kinase genes. , 1990, Oncogene.

[167]  J. Bazan Shared architecture of hormone binding domains in type I and II interferon receptors , 1990, Cell.

[168]  F. Mandelli,et al.  Maintenance treatment with recombinant interferon alfa-2b in patients with multiple myeloma responding to conventional induction chemotherapy. , 1990, The New England journal of medicine.

[169]  R. Eddy,et al.  Identification and chromosomal mapping of new human tyrosine kinase genes. , 1990, Oncogene.

[170]  A. Wilks Two putative protein-tyrosine kinases identified by application of the polymerase chain reaction. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[171]  W. Cendrowski [Interferon in multiple sclerosis]. , 1981, Neurologia i neurochirurgia polska.

[172]  J. Luban SARS-CoV-2 , 2020 .

[173]  W. Liu,et al.  Nuclear RNF2 inhibits interferon function by promoting K33-linked STAT1 disassociation from DNA , 2017, Nature Immunology.

[174]  C. Andrewes,et al.  Virus interference. I. The interferon , 2017 .

[175]  A. Găman Hairy cell leukemia--a rare type of leukemia. A retrospective study on 39 patients. , 2013, Romanian journal of morphology and embryology = Revue roumaine de morphologie et embryologie.

[176]  J. D. Burke,et al.  Antiviral strategies: the present and beyond. , 2009, Current molecular pharmacology.

[177]  Stephen J. Elledge,et al.  Supplemental Data The IFITM Proteins Mediate Cellular Resistance to Influenza A H 1 N 1 Virus , West Nile Virus , and Dengue Virus , 2009 .

[178]  D. Alberts,et al.  Randomized trial of adjuvant intraperitoneal alpha-interferon in stage III ovarian cancer patients who have no evidence of disease after primary surgery and chemotherapy: An intergroup study. , 2006, Gynecologic oncology.

[179]  N. Cordani,et al.  The relative endogenous expression levels of the IFNAR2 isoforms influence the cytostatic and pro-apoptotic effect of IFNalpha on pleomorphic sarcoma cells. , 2005, International journal of oncology.

[180]  S. Fuchs,et al.  SCF(HOS) ubiquitin ligase mediates the ligand-induced down-regulation of the interferon-alpha receptor. , 2003, The EMBO journal.

[181]  A. Lewis-Antes,et al.  IFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complex. , 2003, Nature immunology.

[182]  A. Eggermont Critical appraisal of IFN-alpha-based adjuvant therapy in stage II-III malignant melanoma. , 2002, Expert review of anticancer therapy.

[183]  A. Verma,et al.  Protein kinase C-delta (PKC-delta ) is activated by type I interferons and mediates phosphorylation of Stat1 on serine 727. , 2002, The Journal of biological chemistry.

[184]  R. Silverman,et al.  Skin allograft rejection is suppressed in mice lacking the antiviral enzyme, 2',5'-oligoadenylate-dependent RNase L. , 2002, Viral immunology.

[185]  John Kirkwood,et al.  Cancer immunotherapy: the interferon-alpha experience. , 2002, Seminars in oncology.

[186]  C. Pickart,et al.  Mechanisms underlying ubiquitination. , 2001, Annual review of biochemistry.

[187]  S. Krown Interferon-alpha: evolving therapy for AIDS-associated Kaposi's sarcoma. , 1998, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

[188]  B. Williams,et al.  Identification of genes differentially regulated by interferon alpha, beta, or gamma using oligonucleotide arrays. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[189]  J. Harris,et al.  Recombinant human interferon-beta in the treatment of condylomata acuminata. , 1997, International journal of STD & AIDS.

[190]  L. Platanias,et al.  A region of the beta subunit of the interferon alpha receptor different from box 1 interacts with Jak1 and is sufficient to activate the Jak-Stat pathway and induce an antiviral state. , 1997, The Journal of biological chemistry.

[191]  T. Maniatis,et al.  Regulation of interferon-gamma-activated STAT1 by the ubiquitin-proteasome pathway. , 1996, Science.

[192]  B. Cohen,et al.  The human interferon alpha/beta receptor: characterization and molecular cloning. , 1994, Cell.

[193]  G. Gahrton,et al.  Natural interferon-alpha in combination with melphalan/prednisone versus melphalan/prednisone in the treatment of multiple myeloma stages II and III: a randomized study from the Myeloma Group of Central Sweden. , 1993, Blood.

[194]  G. Lutfalla,et al.  Genetic transfer of a functional human interferon alpha receptor into mouse cells: cloning and expression of its cDNA. , 1990, Cell.

[195]  H. Heimpel,et al.  Deficient IFN alpha production in hairy cell leukemia. , 1986, Blut.

[196]  Y. Kojima,et al.  [Inhibition of vaccinia infection by a liquid factor in tissues infected by homologous virus]. , 1958, Comptes rendus des seances de la Societe de biologie et de ses filiales.

[197]  M. Jiang,et al.  Nuclear RNF 2 inhibits interferon function by promoting K 33-linked STAT 1 disassociation from DNA , 2022 .